The Washington Post on MSN6d
FDA approves weight-loss drug Zepbound to treat sleep apneaThe Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...
A growing body of research is finding a robust link between diet and sleep quality. But it’s not just the usual suspects like ...
However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...
WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...
Inquirer on MSN5d
US approves first-ever obstructive sleep apnea drugOn December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...
Verywell Health on MSN4d
Zepbound Gets FDA Approval to Treat Sleep ApneaThe obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.
Major health insurance providers in India — both public and private — exclude sleep disorders from their plans. This coverage ...
Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback